Consensus Omeros Corporation

Stocks

OMER

US6821431029

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 00:00:00 27/06/2026 +04			5-day change	1st Jan Change
8.670 ^USD	-19.12%		-15.66%	-49.52%

06-26	Omeros Corporation Provides Update On European Marketing Authorization Application For Narsoplimab In TA-TMA	CI
06-26	Omeros to Seek EMA Review After Negative Opinion on Narsoplimab Marketing Application	MT

Evolution of the Average Target: Omeros Corporation

Evolution of the Target Price: Omeros Corporation

Changes in Analyst Recommendations: Omeros Corporation

7fd1a437cacc32623a646c3d.FwhLcZZRH8MqwjunieUIWMiXX8DPBSu5ThOgmSXHd9w.RmAtRqUnT-5-h1HpxYtDdaCmHZagT2_SDUnP23KDEbpnex4ezzJ5mV-lCw~88e7de0d7f7c70dd34a29e6df7270507

Analysts' recommendations: Omeros Corporation

15/10/25	Omeros Shares Surge Pre-Bell After Asset Purchase, License Deal With Novo Nordisk	MT
10/06/25	HC Wainwright Initiates Coverage on Omeros With Buy Rating, $9 Price Target	MT
15/03/23	UBS Adjusts Omeros Price Target to $4 From $2, Maintains Neutral Rating	MT
08/12/22	UBS Downgrades Omeros to Neutral From Buy, Adjusts Price Target to $2 From $12	MT
09/11/22	BofA Securities Downgrades Omeros to Underperform Rating From Neutral, Price Target is $3	MT
08/06/22	BofA Securities Downgrades Omeros to Neutral From Buy, Sets $4 Price Target	MT
18/01/22	Cantor Fitzgerald Adjusts Omeros' Price Target to $20 From $34, Reiterates Overweight Rating	MT
19/10/21	OMEROS : HC Wainwright Adjusts Price Target on Omeros to $12 From $19, Maintains Buy Rating	MT
15/10/21	OMEROS : UBS Adjusts Price Target on Omeros to $13 From $25 on Drug Filing Deficiencies, Maintains Buy Rating	MT
11/10/21	OMEROS : Wedbush Suspended Coverage on Omeros	MT
08/10/21	OMEROS : JPMorgan Downgrades Omeros to Underweight from Neutral	MT
06/10/21	OMEROS : HC Wainwright Adjusts Omeros' Price Target to $19 from $32, Keeps Buy Rating	MT
04/10/21	OMEROS : Maxim Downgrades Omeros to Hold from Buy	MT
01/10/21	OMEROS : Wedbush Downgrades Omeros to Underperform From Neutral, Lowers PT to $5 From $18 After FDA Delays PDUFA For Narsoplimab	MT
01/10/21	OMEROS : Maxim Group Downgrades Omeros to Hold From Buy	MT
27/09/21	OMEROS : JPMorgan Starts Omeros at Neutral With $15 Price Target	MT
18/06/21	OMEROS : WBB Securities Reinstates Omeros With Strong Buy, $100 Price Target	MT
26/04/21	OMEROS : HC Wainwright Adjusts Omeros' Price Target to $32 From $34, Keeps Buy Rating	MT
01/02/21	OMEROS : UBS Starts Omeros at Buy With $25 Price Target	MT
20/01/21	OMEROS : HC Wainwright Adjusts Omeros' Price Target to $34 from $31, Keeps Buy Rating	MT
20/01/21	OMEROS : Wedbush Adjusts Omeros' Price Target to $18 From $13, Maintains Neutral Rating	MT
04/12/20	OMEROS : Maxim Adjusts Omeros' Price Target to $25 from $20, Keeps Buy Rating	MT
17/11/20	OMEROS : Wedbush Adjusts Omeros' Price Target to $13 From $12, Maintains Neutral Rating	MT

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' Target price divergence	Objective/dr gap
OMEROS CORPORATION	-	+280.62%
ARGENX SE		+10.79%
WUXI APPTEC CO., LTD.		+23.51%
BIONTECH SE		+35.78%
INSMED INCORPORATED		+90.61%
WUXI BIOLOGICS (CAYMAN) INC.		+41.85%
GENMAB A/S		+35.91%
EXELIXIS, INC.		-9.62%
PHARMAESSENTIA CORPORATION		-21.53%
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.		+31.01%
Average		+51.89%
Weighted average by Cap.		+26.98%